Receives NSF CAREER Award
Xavier Intes, assistant professor in the Department of Biomedical Engineering, has won a prestigious Faculty Early Career Development Award (CAREER) from the National Science Foundation (NSF).
Intes will use the five-year, $400,000 award to further his research into a promising non-invasive biomedical imaging technique to help identify and treat cancerous tumors. The CAREER Award is given to faculty members at the beginning of their academic careers and is one of NSF’s most competitive awards, placing emphasis on high-quality research and novel education initiatives.
“We congratulate Xavier for receiving the NSF CAREER Award in recognition of his potential as a young researcher at Rensselaer,” said David Rosowsky, dean of the School of Engineering. “Dr. Intes and his students are working on leading-edge optical molecular imaging techniques, and we look forward to their new findings and discoveries in the coming years. Xavier joins a growing list of NSF CAREER Award recipients in the School of Engineering. We are enormously proud to count him among this impressive group of faculty.”
With his research, Intes seeks to exploit optical imaging technologies and equip physicians and researchers with new tools in the fight against cancer. Leveraging the power of these optical imaging and spectroscopy systems could expand our ability to screen for diseases, detect diseases earlier, and lead to more accurate diagnoses, safer therapy, and better monitoring of the healing process. One of Intes’ long-term research goals is to advance Forster Resonance Energy Transfer (FRET) as a robust, 3-D imaging platform for in vivo profiling of tumors and to devise individualized therapeutic regimen. Used in microscopy and spectroscopy, FRET is a non-invasive, non-radioactive optical technique to observe protein interactions at the nanoscale. Currently, FRET
applications are limited to observing interactions
in cell cultures or Petri dish environments.
With his CAREER project, titled “Whole-Body FRET Tomography,” Intes will adapt FRET to observe protein interactions in live animals. This is an important step, Intes said, in order to better see if experimental cancer drugs are working. Many new drugs are designed to actively seek out a tumor inside the body, and FRET is an easy, non-invasive, harmless means to detect whether the drug successfully located and interacted with the tumor. The new FRET optical system uses light to sense and quantify biomarker recognition and create 3-D visual images of drug distribution and interaction in the live animals.
Prior to joining the Rensselaer faculty in 2007, Intes conducted research into biophotonics and biomedical instrumentation as chief scientist at Advanced Research Technologies in Montreal. He is a member of the Optical Society of America and the International Society of Biomedical Imaging. Intes serves as an active reviewer of numerous science and engineering journals, was the editor of the 2008 book Translational Multimodality Optical Imaging, and
has published more than 40 papers in leading international journals. Additionally, Intes chairs
the Multimodal Biomedical Imaging international conference held annually in San Jose, Calif.
At Rensselaer, Intes is a member of the Center for Biotechnology and Interdisciplinary Studies, the Center for Engineering-based Patient Modeling, the Center for Modeling, Simulation and Imaging in Medicine, and the Scientific Computation Research Center.
In addition to the NSF, Intes receives research funding from the National Cancer Institute and the National Institute of Biomedical Imaging and Bioengineering.
Intes received bachelor’s, master’s, and doctoral degrees in physics from the Universite de Bretagne Occidentale in France.
For additional information on Intes’ research at Rensselaer, go to intes-lab.bme.rpi.edu/index.shtml.